# Safety and Efficacy of Zemplar Capsule in Reducing Serum iPTH Levels in Chronic Kidney Disease Subjects (Three Times Weekly)

> **NCT00048451** · PHASE3 · COMPLETED · sponsor: **Abbott** · enrollment: 68 (—)

## Conditions studied

- Renal Insufficiency, Chronic

## Interventions

- **DRUG:** paricalcitol

## Key facts

- **NCT ID:** NCT00048451
- **Lead sponsor:** Abbott
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-02
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 68 (—)
- **Last updated:** 2006-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00048451

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00048451, "Safety and Efficacy of Zemplar Capsule in Reducing Serum iPTH Levels in Chronic Kidney Disease Subjects (Three Times Weekly)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00048451. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*